<DOC>
	<DOC>NCT02013830</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of oral Xeloda (capecitabine) plus intravenous Avastin (bevacizumab) in patients with advanced or metastatic liver cancer. The anticipated time on study treatment is 3-12 months.</brief_summary>
	<brief_title>A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer</brief_title>
	<detailed_description />
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>adult patients &gt;=18 years of age; advanced or metastatic liver cancer; &gt;=1 measurable lesion. current radiotherapy, chemotherapy, or other experimental therapies; prior cytotoxic chemotherapy; major surgery, open biopsy, or traumatic injury within 28 days of study entry; history of a malignancy during the last 5 years, other than cutaneous basal cell cancer or in situ cervical cancer.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>